CSL Behring buys Calimmune for $91mm up front plus $325mm in earn-outs
- Gene Therapy, Cell Therapy
- Large Molecule
- Acquisition of Private Biotech
- Payment Includes Cash
- Full Acquisition
- Includes Earnout
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.